

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4941478

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
REFINE, LLC		04/16/2018
RECEIVING PARTY DATA		
Name:	SINCLAIR PHARMACEUTICALS LIMITED	
Street Address:	EDEN HOUSE, LAKESIDE	
Internal Address:	CHESTER BUSINESS PARK	
City:	CHESTER	
State/Country:	UNITED KINGDOM	
Postal Code:	CH4 9QT	
PROPERTY NUMBERS Total: 27		
Property Type	Number	
Patent Number:	8480557	
Patent Number:	9549804	
Patent Number:	8632454	
Patent Number:	7837613	
Patent Number:	9220589	
Patent Number:	9763770	
Application Number:	13936945	
Application Number:	14498940	
Application Number:	14752583	
Application Number:	15413272	
Application Number:	11866985	
Application Number:	13284832	
Application Number:	13609069	
Application Number:	14721957	
Application Number:	60828006	
Application Number:	60933179	
PCT Number:	US2007080356	
Application Number:	12400751	
Application Number:	13476942	

PATENT

Property Type	Number
Application Number:	13784691
Application Number:	15682318
Application Number:	61034935
Application Number:	61106522
PCT Number:	US2009036587
Application Number:	15706401
Application Number:	61110409
PCT Number:	US2009062879

CORRESPONDENCE DATA

Fax Number: (949)760-9502

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (949)760-0404

Email: efiling@knobbe.com

Correspondent Name: KNOBBE, MARTENS, OLSON & BEAR, LLP

Address Line 1: 2040 MAIN STREET

Address Line 2: 14TH FLOOR

Address Line 4: IRVINE, CALIFORNIA 92614

ATTORNEY DOCKET NUMBER:	RFINE.000GEN
NAME OF SUBMITTER:	CASEY D. DONAHOE
SIGNATURE:	/Casey D. Donahoe/
DATE SIGNED:	05/01/2018

Total Attachments: 5

source=Assignment_RFINE#page1.tif

source=Assignment_RFINE#page2.tif

source=Assignment_RFINE#page3.tif

source=Assignment_RFINE#page4.tif

source=Assignment_RFINE#page5.tif

ASSIGNMENT

WHEREAS, **Refine, LLC**, a Georgia corporation having offices at 1813 Empire Industrial Court, Santa Rosa, California 95403 (hereinafter "ASSIGNOR") and **Sinclair Pharmaceuticals Limited**, an England and Wales corporation having offices at Office Village, Chester Business Park, Chester, CH4 9QZ, United Kingdom (hereinafter "ASSIGNEE") entered into that certain Business Purchase Agreement dated June 16, 2017 by and among ASSIGNOR, ASSIGNEE, and the other parties thereto (the "Purchase Agreement"); and

WHEREAS, under the Purchase Agreement, ASSIGNEE completed the purchase of ASSIGNOR's entire right, title, and interest in and to the inventions disclosed in certain patents and patent applications identified below ("Patents and Patent Applications"), and the parties now desire to execute this Assignment in furtherance of the Patents and Patent Applications transferred pursuant to the Purchase Agreement:

Patent No.	Issue Date	Title
US 8,480,557	July 9, 2013	NONAUGMENTIVE MASTOPEXY
US 9,549,804	January 24, 2017	NONAUGMENTIVE MASTOPEXY
AU 2007303137	July 24, 2014	MINIMALLY INVASIVE TISSUE SUPPORT
CA 2665209	January 5, 2016	MINIMALLY INVASIVE TISSUE SUPPORT
US 8,632,454	January 21, 2014	MINIMALLY INVASIVE TISSUE SUPPORT SYSTEM AND METHOD WITH A SUPERIOR TISSUE SUPPORT AND AN INFERIOR ANCHOR
US 7,837,613	November 23, 2010	MINIMALLY INVASIVE BREAST LIFT METHOD WITH A SUPERIOR TISSUE SUPPORT AND AN INFERIOR ANCHOR
US 9,220,589	December 29, 2015	MINIMALLY INVASIVE BREAST LIFT METHOD WITH A SUPERIOR TISSUE SUPPORT AND AN INFERIOR ANCHOR
US 9,763,770	September 19, 2017	MINIMALLY INVASIVE BREAST LIFT METHOD WITH A SUPERIOR TISSUE SUPPORT AND AN INFERIOR ANCHOR

Application No.	Filing Date	Title
US 13/936945	July 8, 2013	NONAUGMENTIVE MASTOPEXY
US 14/498940	September 26, 2014	NONAUGMENTIVE MASTOPEXY
US 14/752583	June 26, 2015	NONAUGMENTIVE MASTOPEXY
US 15/413272	January 23, 2017	NONAUGMENTIVE MASTOPEXY
US 11/866985	October 3, 2007	MINIMALLY INVASIVE TISSUE SUPPORT
US 13/284832	October 28, 2011	MINIMALLY INVASIVE TISSUE SUPPORT
US 13/609069	September 10, 2012	MINIMALLY INVASIVE TISSUE SUPPORT
US 14/721957	May 26, 2015	MINIMALLY INVASIVE TISSUE SUPPORT
US 60/828006	October 3, 2006	TISSUE LIFT AND SUPPORT MEANS
US 60/933179	June 4, 2007	APPARATUS AND METHODS FOR MINIMALLY INVASIVE MASTOPEXY
EP 07843781.1	October 3, 2007	MINIMALLY INVASIVE TISSUE SUPPORT
JP 2009-531594	October 3, 2007	MINIMALLY INVASIVE TISSUE SUPPORT
PCT/US2007/080356	October 3, 2007	MINIMALLY INVASIVE TISSUE SUPPORT
US 12/400751	March 9, 2009	MINIMALLY INVASIVE TISSUE SUPPORT
US 13/476942	May 21, 2012	MINIMALLY INVASIVE TISSUE SUPPORT
US 13/784691	March 4, 2013	MINIMALLY INVASIVE TISSUE SUPPORT
US 15/682318	August 21, 2017	MINIMALLY INVASIVE TISSUE SUPPORT
US 61/034935	March 7, 2008	MINIMALLY INVASIVE TISSUE SUPPORT
US 61/106522	October 17, 2008	MINIMALLY INVASIVE TISSUE SUPPORT
PCT/US2009/036587	March 9, 2009	MINIMALLY INVASIVE TISSUE SUPPORT
US 15/706401	September 15, 2017	MINIMALLY INVASIVE BREAST LIFT METHOD WITH A SUPERIOR TISSUE

		SUPPORT AND AN INFERIOR ANCHOR
EP 09824201.9	October 30, 2009	MINIMALLY INVASIVE TISSUE SUPPORT SYSTEM AND METHOD WITH A SUPERIOR TISSUE SUPPORT AND AN INFERIOR ANCHOR
US 61/110409	October 31, 2008	MINIMALLY INVASIVE TISSUE SUPPORT
PCT/US2009/062879	October 30, 2009	MINIMALLY INVASIVE TISSUE SUPPORT SYSTEM AND METHOD WITH A SUPERIOR TISSUE SUPPORT AND AN INFERIOR ANCHOR

NOW, THEREFORE, for the mutual consideration set forth in the Purchase Agreement and other good and valuable consideration, the receipt of which is hereby acknowledged, and subject to the terms and conditions of the Purchase Agreement, ASSIGNOR hereby further acknowledges and confirms that it has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer, unto ASSIGNEE, its successors, legal representatives, and assigns, ASSIGNOR's entire right, title, and interest, if any, throughout the world in, to, and under the said improvements, and the said Patents and Patent Applications and all Patents that may be granted thereon, and all provisional applications relating thereto, and all divisions, continuations, continuations-in-part, reissues, reexaminations, renewals, and extensions thereof, and all rights of priority under International Conventions and applications for Letters Patent that may hereafter be filed for said improvements or for the said Patents and Patent Applications in any country or countries foreign to the United States; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patents for said improvements and all Letters Patents resulting from the Patents and Patent Applications to ASSIGNEE, its successors, legal representatives, and assigns, in accordance with the terms of this Agreement.

ASSIGNOR does hereby sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the Letters Patents before or after issuance;

ASSIGNOR hereby covenants and agrees that it will communicate to ASSIGNEE, its successors, legal representatives, and assigns any facts known to ASSIGNOR respecting the Patents and Patent Applications immediately upon becoming aware of those facts, and that it will testify in any legal proceeding involving any of the Patents and Patent Applications, will sign all lawful papers, execute all divisional, continuing, and reissue applications, make all rightful

PATENT

Client Code: RFINE.000GEN

Page 4

oaths, and will generally do everything possible to aid ASSIGNEE, its successors, legal representatives, and assigns to obtain and enforce the Patents and Patent Applications in all countries.

PATENT

REEL: 045686 FRAME: 0208

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 16th day of April, 2018.

Assignor (Conveying Party)
Refine, LLC

Assignee (Receiving Party)
Sinclair Pharmaceuticals Limited

By: [Signature]

By: [Signature]

Name: MICHAEL J LEE

Name: ALAN DUBY

Title: VP of R&D

Title: CHIEF FINANCIAL OFFICER

Date: 9 APR 2018

Date: 16th APRIL 2018

Witnessed
by: [Signature]

Witnessed
by: [Signature]

Witness
Name: Kristina Lee

Witness
Name: ALICE MINZA-CLARK

27585336